Name | Number of supported studies | Average coverage | |
---|---|---|---|
neuron | 5 studies | 30% ± 12% | |
endothelial cell | 5 studies | 22% ± 4% | |
glutamatergic neuron | 5 studies | 46% ± 20% | |
epithelial cell | 5 studies | 27% ± 9% | |
astrocyte | 5 studies | 26% ± 9% | |
oligodendrocyte | 5 studies | 24% ± 5% | |
GABAergic neuron | 4 studies | 43% ± 14% | |
oligodendrocyte precursor cell | 4 studies | 27% ± 7% | |
interneuron | 4 studies | 34% ± 17% | |
macrophage | 3 studies | 19% ± 3% | |
transit amplifying cell | 3 studies | 28% ± 12% |
Name | Number of supported studies | Average coverage | |
---|---|---|---|
brain | 5 studies | 40% ± 13% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
esophagus | 100% | 2203.20 | 1443 / 1445 | 100% | 44.14 | 183 / 183 |
breast | 100% | 1780.44 | 459 / 459 | 100% | 32.39 | 1113 / 1118 |
prostate | 100% | 1681.32 | 245 / 245 | 99% | 22.20 | 499 / 502 |
stomach | 100% | 1379.67 | 358 / 359 | 100% | 25.74 | 285 / 286 |
lung | 99% | 1864.86 | 574 / 578 | 100% | 31.30 | 1151 / 1155 |
pancreas | 100% | 1456.90 | 328 / 328 | 99% | 15.36 | 176 / 178 |
bladder | 100% | 1640.67 | 21 / 21 | 99% | 24.59 | 498 / 504 |
brain | 99% | 2813.39 | 2616 / 2642 | 100% | 21.11 | 702 / 705 |
liver | 100% | 2684.57 | 226 / 226 | 99% | 17.24 | 400 / 406 |
uterus | 100% | 1546.59 | 170 / 170 | 98% | 21.59 | 452 / 459 |
intestine | 100% | 1937.08 | 965 / 966 | 98% | 24.50 | 516 / 527 |
ovary | 99% | 1402.68 | 179 / 180 | 98% | 14.40 | 421 / 430 |
thymus | 100% | 1631.89 | 652 / 653 | 96% | 11.97 | 581 / 605 |
skin | 100% | 3945.27 | 1809 / 1809 | 93% | 18.32 | 439 / 472 |
kidney | 99% | 1375.08 | 88 / 89 | 93% | 14.54 | 842 / 901 |
adrenal gland | 100% | 2028.43 | 258 / 258 | 92% | 15.88 | 211 / 230 |
spleen | 100% | 1611.14 | 241 / 241 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 100% | 19.98 | 45 / 45 |
ureter | 0% | 0 | 0 / 0 | 100% | 8.04 | 1 / 1 |
adipose | 100% | 1487.78 | 1203 / 1204 | 0% | 0 | 0 / 0 |
muscle | 99% | 1671.82 | 795 / 803 | 0% | 0 | 0 / 0 |
blood vessel | 98% | 1001.73 | 1304 / 1335 | 0% | 0 | 0 / 0 |
heart | 91% | 1017.93 | 780 / 861 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 90% | 10.79 | 26 / 29 |
eye | 0% | 0 | 0 / 0 | 74% | 10.25 | 59 / 80 |
peripheral blood | 33% | 906.71 | 302 / 929 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0006646 | Biological process | phosphatidylethanolamine biosynthetic process |
GO_0005789 | Cellular component | endoplasmic reticulum membrane |
GO_0005794 | Cellular component | Golgi apparatus |
GO_0004307 | Molecular function | ethanolaminephosphotransferase activity |
GO_0046872 | Molecular function | metal ion binding |
Gene name | SELENOI |
Protein name | Ethanolaminephosphotransferase 1 Ethanolaminephosphotransferase 1 (hEPT1) (EC 2.7.8.1) (Selenoprotein I) (SelI) Selenoprotein I |
Synonyms | SELI EPT1 KIAA1724 |
Description | FUNCTION: Ethanolaminephosphotransferase that catalyzes the transfer of phosphoethanolamine/PE from CDP-ethanolamine to lipid acceptors, the final step in the synthesis of PE via the 'Kennedy' pathway . PE is the second most abundant phospholipid of membranes in mammals and is involved in various membrane-related cellular processes . The enzyme is critical for the synthesis of several PE species and could also catalyze the synthesis of ether-linked phospholipids like plasmanyl- and plasmenyl-PE which could explain it is required for proper myelination and neurodevelopment . . |
Accessions | ENST00000442141.5 ENST00000260585.12 C9JAG1 ENST00000447170.1 C9JEZ2 G1UI38 Q9C0D9 |